HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells

HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells

Aberrant epigenetic regulation is closely associated with drug tolerance, an early step in the acquisition of drug resistance. We previously reported that a pioneer transcriptional factor (also called an epigenetic initiator) rapidly induced by osimertinib, a third-generation epidermal growth factor...

Full description

Saved in:
Bibliographic Details
Main Authors: Hanbing Lyu, Akihiko Ishimura, Ryusuke Suzuki, Khurelsukh Buyanbat, Gerelsuren Batbayar, Makiko Meguro-Horike, Shin-ichi Horike, Seiji Yano, Takeshi Suzuki
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Biochemistry and Biophysics Reports
Subjects:
HDAC5
LMK235
Lung cancer
EGFR-TKI
Osimertinib
Drug resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2405580825001037
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items